Miguel-Angel Perales
Memorial Sloan Kettering Cancer Center
581 Papers
1.2K Citations
Miguel-Angel Perales is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 56, co-authored 379 publications. Previous affiliations of Miguel-Angel Perales include Tufts Medical Center & Cornell University.
Chat about Author
Papers
Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria.
Djamilia Dierov,Nicholas Webb,Samira Fatmi,Chamberlain Nwanne,Cristi Ciolino,Kara Mosesso,Jimmy Nieves,Miguel-Angel Perales,Miguel-Angel Perales,Susan E. Prockop,Doris M. Ponce,Doris M. Ponce +11 more
- 01 Oct 2019
TL;DR: A standardized approach for the assessment of chronic GVHD in accordance with the NIH consensus criteria (NCC) guidelines was established and it was found that the assessment and reporting of GV HD reached 100% compliance.
A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2
Karthik Nath,Sean M. Devlin,Craig S Sauter,M. Lia Palomba,Gunjan L. Shah,Parastoo B. Dahi,Richard J. Lin,Michael Scordo,Miguel-Angel Perales,Lori A. Leslie,Roni Shouval,Sara Bekele,E. Cathcart,Elena Mead,Bianca Santomasso,Andrei Holodny,Renier J. Brentjens,Isabelle Riviere,Michel Sadelain,Jae H. Park +19 more
TL;DR: A phase 2 trial of prophylactic anakinra in patients receiving commercial anti-CD19 CAR-T for r/r B-cell lymphoma and results are reported on rates of severe CRS, all grade CRS and ICANS, overall response rate (ORR), survival outcomes, and serum and CSF biomarker levels.
From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better
Giovanna Melica,Alejandro Luna De Abia,Magdalena Corona,Joshua A Fein,Parastoo B. Dahi,Sergio A. Giralt,I. Landego,Richard J. Lin,M. Lia Palomba,Allison Parascondola,Jae H. Park,Gilles Salles,Amethyst Saldia,Michael Scordo,Ana Alarcon Tomas,Gunjan L. Shah,Roni Shouval,Ying Taur,Miguel-Angel Perales,Susan K. Seo +19 more
TL;DR: This large single-center cohort of R/R lymphoma patients after CAR T-cell therapy offers a valuable snapshot of two different antifungal prophylactic approaches with remarkably low rates of IFI in both strategies, even after the 2020 guideline update with more restrictive ant ifungal use.
Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
Parastoo B. Dahi,Sheila Kenny,Jessica Flynn,Sean M. Devlin,Josel D. Ruiz,Stephanie Chinapen,Oscar B Lahoud,Matthew J. Matasar,Craig H. Moskowitz,Miguel-Angel Perales,Gunjan L. Shah,Craig S. Sauter,Sergio Giralt,Alexander I Geyer,Ann A. Jakubowski +14 more
TL;DR: This study illustrates the impact of treatment regimens on PFT changes, but did not demonstrate a predictive value of scheduled PFTs in identifying clinically significant post-AHCT lung disease.
Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy.
TL;DR: This article summarizes 3 patient cases, focusing on the important aspects of patient selection for CAR T-cell therapy, and identifies ideal candidates for CD19-targeting CAR T cells, which, when reintroduced to the patient, identify and kill CD19+ B cells.